tldrdailynews.com logo

Regeneron Libtayo combo fails in melanoma trial against Keytruda

1 min read
Source: Seeking Alpha
Regeneron Libtayo combo fails in melanoma trial against Keytruda
Photo: Seeking Alpha
TL;DR Summary

Regeneron disclosed a late-stage trial evaluating a Libtayo-based combination for melanoma failed to meet its endpoints when compared with Merck’s Keytruda, sparking investor scrutiny of Regeneron’s cancer-immunotherapy program.

Topics:business#healthcare#keytruda#libtayo#melanoma#merck#regeneron
Share this article
  1. Regeneron fails in study for Libtayo combo (REGN:NASDAQ)  Seeking Alpha
  2. Regeneron’s Fianlimab Misses Statistical Significance in Melanoma Trial  The Clinical Trial Vanguard
  3. Balazs Halmos: A Decade into Alternate Immune Checkpoints and LAG-3 Continues to Lag  Oncodaily
  4. BofA reiterates Regeneron stock rating after melanoma trial miss By Investing.com  Investing.com Nigeria
  5. Regeneron's LAG-3 inhibitor combo falls short in late-stage melanoma study  FirstWord Pharma

Reading Insights

Total Reads

0

Unique Readers

3

Time Saved

2 min

vs 2 min read

Condensed

93%

400 → 28 words

Want the full story? Read the original article

Read on Seeking Alpha